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Abstract
Autophagy has been linked with melanoma risk and survival, but no polymor-
phisms in autophagy- related (ATG) genes have been investigated in relation to 
melanoma progression. We examined five single- nucleotide polymorphisms 
(SNPs) in three ATG genes (ATG5; ATG10; and ATG16L) with known or sus-
pected impact on autophagic flux in an international population- based case–
control study of melanoma. DNA from 911 melanoma patients was genotyped. 
An association was identified between (GG) (rs2241880) and earlier stage at 
diagnosis (OR 0.47; 95% Confidence Intervals (CI) = 0.27–0.81, P = 0.02) and 
a decrease in Breslow thickness (P = 0.03). The ATG16L heterozygous genotype 
(AG) (rs2241880) was associated with younger age at diagnosis (P = 0.02). Two 
SNPs in ATG5 were found to be associated with increased stage (rs2245214 
CG, OR 1.47; 95% CI = 1.11–1.94, P = 0.03; rs510432 CC, OR 1.84; 95% 
CI = 1.12–3.02, P = 0.05). Finally, we identified inverse associations between 
ATG5 (GG rs2245214) and melanomas on the scalp or neck (OR 0.20, 95% 
CI = 0.05–0.86, P = 0.03); ATG10 (CC) (rs1864182) and brisk tumor infiltrat-
ing lymphocytes (TILs) (OR 0.42; 95% CI = 0.21–0.88, P = 0.02), and ATG5 
(CC) (rs510432) with nonbrisk TILs (OR 0.55; 95% CI = 0.34–0.87, P = 0.01). 
Our data suggest that ATG SNPs might be differentially associated with specific 
host and tumor characteristics including age at diagnosis, TILs, and stage. These 
associations may be critical to understanding the role of autophagy in cancer, 
and further investigation will help characterize the contribution of these variants 
to melanoma progression.
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Introduction
Autophagy is one mechanism of tumorigenesis that is 
under intensive investigation. This catabolic process assists 
the removal of unnecessary or dysfunctional cellular com-
ponents, including damaged proteins and organelles 
through lysosomal degradation [1]. Autophagy is tightly 
regulated, plays a role in a wide variety of normal physi-
ological processes including energy metabolism, stress 
responses, growth regulation, and aging [2, 3], and can 
be induced in response to nutrient deprivation [4]. 
Macroautophagy (hereafter referred to as autophagy) 
digests dysfunctional macromolecules and damaged orga-
nelles. Accumulating evidence indicates that autophagy is 
involved in cancer development and progression [3, 5], 
and the notion that melanomas are addicted to autophagy 
[5–9] has important implications for cancer development 
as well as management of treatment options for this dif-
ficult disease [10]. The American Cancer Society estimates 
that in 2016, 76,380 new melanomas will be diagnosed 
in the United States and 10,130 people will die from 
their disease [11]. The long- term prognosis for melanoma 
patients has not improved at the same rate as other can-
cers [12].
There are several clinical trials currently ongoing at 
the National Institutes of Health to examine targeting 
inhibition of the autophagic pathway in multiple cancer 
types including melanoma [13]. However, the extent to 
which the rate of autophagic flux impacts melanoma 
development and progression remains to be 
elucidated.
Single- nucleotide polymorphisms (SNPs) have been 
found to be associated with risk and/or prognosis in 
numerous cancers including breast, thyroid, prostate, 
colorectal, and gastric cancer [14–17]. However, to our 
knowledge, there are no studies examining the relation-
ship between ATG SNPs and stage or histopathological 
markers in melanoma. We hypothesized that variants in 
ATG genes may affect gene expression and ultimately 
influence the rate of autophagic flux and impact mela-
noma progression. To test this hypothesis, we analyzed 
germline DNA samples for variants (i.e., SNPs) in three 
ATG genes in a population- based cohort of melanoma 
patients. The SNPs investigated were chosen for having 
a functional impact on disease risk and/or progression 
and have been identified as significantly associated in 
the current literature with disease outcomes and ≥10% 
minor allele frequency in Caucasians [15, 18–21]. In 
particular, the SNP in ATG16L (rs2241880) has been 
reported to create a caspase cleavage site in ATG16L, 
resulting in an unstable protein and decreased autophagy. 
Importantly, this autophagy SNP has been shown as 
causative for Crohn’s disease [22].
Materials and Methods
A total of 3,578 individuals with melanoma from nine 
study sites including eight population- based cancer reg-
istries in the United States (New Jersey, North Carolina, 
and California), Australia (New South Wales and 
Tasmania), Canada (Ontario and British Columbia), and 
Italy (Turin), and one hospital center in Michigan were 
enrolled in the Genes, Environment and Melanoma (GEM), 
a large international population- based study. GEM recruit-
ment procedures and data collection have been previously 
described [23]. The Institutional Review Boards of all 
participating institutions approved the protocol and writ-
ten informed consent was obtained from each 
participant.
Participant selection
From a total of 1206 individuals with multiple primary 
melanoma and 2372 with single primary melanoma, 911 
participants who had extracted DNA available for geno-
typing and for whom tumor tissue was currently available 
(for purposes of future functional studies) were selected 
(Table 1) [24]. DNA was isolated from buccal cells as 
previously described [23, 25]. A Nanodrop 2000 spectro-
photometer (ThermoFisher Scientific, Grand Island, NY) 
was used for quantification of DNA.
Clinical Stage
Histopathology slides were reviewed as previously described 
[26]. Mitoses were defined as present or absent; and tumor 
infiltrating lymphocytes (TIL) grade was scored as absent, 
nonbrisk, or brisk using a previously defined grading 
system [26]. We used T classification, which describes 
the state of the primary tumor in the American Joint 
Committee on Cancer (AJCC) TNM (tumor, regional 
nodes, and distant metastasis) melanoma staging system 
to determine tumor stage based on Breslow thickness, 
mitotic index, and ulceration.
Selection of SNPs and genotyping
Five SNPs in three critical ATG genes (ATG5 rs2245214 
C >G rs510432 T >C; ATG10 rs1864182 A >C, rs1051423 
T >C; ATG16L rs2241880 A>G) were selected from func-
tional SNPs in the literature or that were associated with 
cancer or disease outcomes [15, 18, 19, 21, 27] (see Fig. 1). 
Five Taqman Real- Time PCR Genotyping Assays 
(ThermoFisher Scientific, Grand Island, NY) were used to 
identify SNPs in ATG genes performed with a 7900HT 
Fast Real- Time PCR System (ThermoFisher Scientific, Grand 
Island, NY) following manufacture recommendations. The 
3338 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
K. A. M. White et al.Autophagy SNPs in Melanoma
ratio of fluorescence in amplification during the logarithmic 
phase was quantified to identify specific alleles in genes of 
interest using a commercially available Taqman primer assay 
on a 7900HT Applied Biosystems qPCR machine. The 
genotyping call rates ranged from 96% to 99%, and bio-
logical replicates were generated for 10% of the samples 
with 100% concordance.
Data analysis
To assess genotyping quality, we calculated the genotype 
call rates and tested the departure from Hardy- Weinberg 
Equilibrium for each SNP. SNPs were modeled as a three- 
level nominal variable. Linear regression analyses were 
performed to assess the association between SNPs and 
log- transformed Breslow thickness. We used the log- 
transformed Breslow thickness to correct for the non-
normal distribution and back- transformed model 
coefficients so that results represent increases in Breslow 
thickness per 1 mm. To evaluate the association between 
ATG SNPs and histopathological features, we conducted 
binary logistic regression analyses for mitosis (presence 
or absence), ulceration (presence or absence), early versus 
late stage (early- T1a/T1b/T2a vs. late- stage T2b and 
higher), ordinal logistic regression for continuous stage 
(T1a though T4b), and polytomous logistic regression for 
histology and tumor subtype. Odds Ratios (ORs) and 
95% Confidence Intervals (CI) estimated from logistic 
regression models are presented. We conducted multivari-
able modeling to account for covariates and Wald tests 
were used to assess the significance of the association. 
Statistical tests were two sided with P < 0.05 considered 
statistically significant. Using a genotypic model to simul-
taneously compare heterozygous genotype to wildtype, 
and homozygous minor genotype to wildtype, we report 
a global P- value representing the overall significance of 
the two comparisons for analysis.
Results
Genotype frequencies are presented in Table 2, and geno-
types did not deviate from Hardy- Weinberg proportions 
(data not shown). The distribution of SNP genotypes at 
the five ATG genes was similar in males and females 
(data not shown). After adjustments for age, gender, status 
(SPM or MPM) and study center, three ATG SNPs—
rs2241880, rs510432, rs2245214—were inversely associated 
with several melanoma prognostic indicators (Tables 3, 
4 and Table S2; Fig. 1). In separate analyses of each SNP 
with Breslow thickness, the ATG16L rs2241880 GG geno-
type was associated with a decrease in Breslow thickness 
(P = 0.02), earlier stage at diagnosis (OR 0.47; 95% 
CI = 0.27–0.81, P = 0.02). Additionally, rs2241880 het-
erozygosity (AG) was associated with a younger age of 
diagnosis (P = 0.02).
ATG5 rs2245214 (AA) and ATG5 rs510432 (CC) were 
positively associated with later stage (OR 1.47; 95% 
CI = 1.11–1.94, P = 0.03; OR 1.84; 95% CI = 1.12–3.02, 
P = 0.05) (Table 4). The homozygous variant (CC) of 
rs510432 also had a borderline association with later stage.
SNP rs1864182 (CC) and rs510432 (CC) were inversely 
associated with brisk TILs (OR 0.42; 95% CI = 0.21–0.88, 
P = 0.02; OR 0.55; 95% CI = 0.34–0.87, P = 0.01, respec-
tively) as well as the presence of nonbrisk TILs (Table 
S2). Finally, rs2245214 (GG) was inversely associated with 
scalp/neck melanomas (OR 0.20; 95% CI = 0.05–0.86, 
P = 0.03), although there was not a global association 
of this SNP with anatomic site of melanoma (Table S2). 
No associations between the five autophagy SNPs and 
mitosis, ulceration, or histological subtype (Table S2) were 
Figure 1. Overview of the Autophagy related (ATG) conjugation pathway including significant associations with SNPs investigated in this study, 
including those in the ATG5, ATG10 and ATG16L genes.
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identified. We also did not identify an association between 
any of the five SNPs and melanoma survival.
Discussion
Despite clear associations between autophagy and cancer 
etiology [28–30], the role of germline SNPs in melanoma 
stage at diagnosis has remained unexplored. Autophagy 
in cancer is context dependent, acting as both a tumor 
suppressor and tumor promotor depending on the stage 
of development of the tumor [31]. While a recent meta- 
analysis of GWAS studies did not observe an association 
between ATG gene SNPs and melanoma susceptibility 
[32], we know of no other study specifically addressing 
the associations between common genetic variants in ATG 
genes and melanoma survival.
The SNPs investigated in our study are located in genes 
that are critical to the early stage of the autophagy pathway 
(Fig. 1) and necessary for the formation of the autophago-
some [1]. As shown in Figure 1, ATG10 is essential for 
ATG12 conjugation to ATG5 and ultimately to ATG16L.
Previously, variants in ATG genes have been associated 
with risk and/or prognosis in other cancers [15, 18, 19] 
and autoimmune conditions [14, 22, 33]. In this study, 
we examined one SNP (rs2241880) in ATG16L, which 
Table 1. Clinicopathologic characteristics among 911 melanoma cases.
Characteristic No.(%)
Median age at diagnosis 60 years
Median Breslow thickness 0.8 mm
Gender
Male 534 (59)
Female 377 (41)
Breslow thickness (mm)
0.01–1.00 547 (60)
1.01–2.00 212 (23)
2.01–4.00 108 (12)
>4.00 44 (5)
Status
Single primary 603 (66)
Multiple primary 308 (34)
Anatomic site
Trunk/pelvis 394 (43)
Scalp/neck 56 (6)
Face/ears/other 116 (13)
Upper extremities 172 (19)
Lower extremities 173 (19)
Histological subtype
Superficial Spreading Melanoma 610 (67)
Nodular Melanoma 92 (10)
Lentigo Maligna Melanoma 116 (13)
Other 93 (10)
Ulceration
Absent 794 (92)
Present 73 (8)
Missing 44 (0)
Mitosis
Absent 454 (52)
Present 415 (48)
Missing 42 (0)
AJCC stage
T1a 397 (46)
T1b 124 (14)
T2a 183 (21)
T2b 16 (2)
T3a 73 (8)
T3b 32 (4)
T4a 21 (2)
T4b 21 (2)
AJCC stage (T1a/T1b/T2a vs. T2b+)
T1a/T1b/T2a 704 (81)
T2b+ 163 (19)
TIL grade
Absent 194 (22)
Non- Brisk 563 (65)
Brisk 111 (13)
Missing 43 (0)
Growth phase
Absent 255 (29)
Present 614 (71)
Missing 42 (0)
Death from melanoma* 76 (8)
Alive or death from other causes 835 (92)
AJCC, American Joint Committee on Cancer; TIL, Tumor infiltrating lym-
phocytes; *Death from melanoma recorded during 7.5 years of follow- up.
Table 2. Genotypic frequencies of ATG gene polymorphisms tested in 
melanoma cases.
ATG SNP Genotype
Number of patients 
(%)
ATG5
rs510432 CC 190 (0.22)
CT 425 (0.48)
TT 266 (0.30)
Missing  30
ATG5
rs2245214 CC 331 (0.38)
CG 427 (0.49)
GG 110 (0.13)
Missing  43
ATG16L
rs2241880 AA 198 (0.23)
AG 418 (0.490
GG 245 (0.29)
Missing  50
ATG10
rs10514231 CC 116 (0.13)
CT 403 (0.47)
TT 345 (0.40)
Missing  47
ATG10
rs1864182 AA 238 (0.28)
AC 424 (0.49)
CC 200 (0.23)
Missing  49
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increased risk for thyroid cancer and was associated with 
poor disease prognosis. A nonsynonymous polymorphism 
in ATG16L, rs2241880 (T300A), has been extensively stud-
ied in Crohn’s disease [34]. This ATG16L SNP (GG) 
creates a caspase 3 and caspase 7 cleavage site and reduces 
the stability of the protein resulting in decreased autophagy; 
clinically, presence of this variant is associated with 
increased risk of ileal Crohn’s disease in adults and 
decreased survival [34]. While this SNP is associated with 
increased susceptibility, it is also associated with childhood 
(early) onset of Crohn’s disease [35]. As illustrated in 
Figure 1, ATG16L is essential for the formation of the 
autophagosome. Through its noncovalent interaction with 
ATG12–ATG5, it facilitates the conjugation of other critical 
ATG proteins. Two SNPs in ATG5 (rs2241880 and 
rs2245214) have been associated with a nearly twofold 
susceptibility to nonmedullary thyroid cancers [19] and 
rs2241880 is associated with disease severity [18] as well 
as two-fold risk of developing colorectal cancer [16].
ATG5 is part of an ubiquitin- like conjugation pathway 
which links ATG5 with ATG16L (ATG5- ATG16L). 
Specifically, ATG5 membrane binding is activated through 
its conjugation with ATG16L. Membrane binding by the 
ATG12–ATG5–ATG16 exerts an E3 enzyme- like function 
and this binding is critical for the correct formation of 
the autophagosome (Fig. 1). Importantly, both rs1864182 
and rs1051423, located in ATG10, have been reported to 
be associated with a decreased risk of breast cancer [15].
Table 3. Associated clinicopathologic characteristics by genotype status among melanoma cases.
Age at diagnosis, y
ATG gene SNP Genotype1 n Coeff (95% CI) P- value* Global P- value*
rs10514231 TT 864 1.00  
CT  0.22 (−1.95–2.39) 0.84 0.71
CC  1.33 (−1.84–4.50) 0.41
rs1864182 AA 862 1.00  
AC  0.72 (−1.67–3.11) 0.55 0.70
CC  −0.26 (−3.09–2.57) 0.86
rs2241880 AA 861 1.00  
AG  −3.25 (−5.60–0.91) 0.01 0.02
GG  −2.04 (−4.83–0.74) 0.15
rs2245214 CC 868 1.00  
CG  −0.59 (−2.77–1.58) 0.59 0.75
GG  −1.17 (−4.43–2.09) 0.48
rs510432 TT 881 1.00  
CT  0.43 (−1.86–2.73) 0.71 0.75
CC  −0.55 (−3.33–2.23) 0.70
Breslow thickness (Continuous; Exponentiated)
ATG gene SNP Genotype2 Coeff (95% CI) P- value* Global P- value*
rs10514231 TT 1.00  0.18
CT 1.09 (0.98–1.22) 0.09  
CC 0.99 (0.84–1.16) 0.91  
rs1864182 AA 1.00  0.72
AC 1.05 (0.92–1.19) 0.46  
CC 1.05 (0.9–0.82) 0.50  
rs2241880 AA 1.00  0.03
AG 1.04 (0.92–0.85) 0.55  
GG 0.87 (0.97–0.99) 0.06  
rs22445214 CC 1.00  0.28
CG 1.09 (0.98–1.22) 0.11  
GG 1.06 (0.9–1.26) 0.49  
rs510432 TT 1.00  0.30
CT 1.05 (0.94–1.19) 0.37  
CC 1.12 (0.97–1.3) 0.12  
CI, confidence interval; Coeff, coefficient; *P < .05 were considered significant; Bolded results indicate significant associations.
1Genotypic model adjusted for gender, study center. and status.
2Genotypic model adjusted for age (continuous), gender, study center, and status.
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In this study, three SNPs were associated with melanoma 
prognostic indicators: Breslow thickness, stage at diagnosis, 
and TILs. In ATG16L rs 2241880 (GG) was associated 
with decreased Breslow thickness (P = 0.03) and earlier 
stage at diagnosis (OR 0.47; 95% CI = 0.27–0.81, P = 0.02). 
ATG16L rs 2241880 (AG) was also associated with younger 
age at diagnosis (P = 0.02). This SNP is also associated 
in the literature with decreased autophagy and may medi-
ate melanoma progression through the accumulation of 
protein aggregates and damaged organelles in patients [36, 
37]. There is some evidence that decreased autophagy 
may inhibit melanoma tumorgeneis [5, 6]. Furthermore, 
this ATG16L SNP has been associated with increased IL- 
1β production in primary cells [34]. Metastatic melanoma 
cells spontaneously secrete active IL- 1β [38] and the asso-
ciation between melanoma and this ATG variant warrants 
further investigation.
In ATG5, two SNPs, rs510432 (CC) (OR 1.84; 95% 
CI = 1.12–3.02, P = 0.05) and rs2245214 (CG) (OR 1.47; 
95% CI = 1.11–1.94, P = 0.03), were associated with increased 
stage. SNP rs510432 had a borderline association with non-
brisk TILs (OR 0.55; 95% CI = 0.34–0.87, P = 0.01), 
Table 4. Relationship Between ATG Genotype and AJCC Stage in Melanoma.
Melanoma Stage 
(≥ Stage T2b vs. Stage T1a/T1b/T2a)
ATG gene SNP Genotype
≥ Stage T2b versus Stage 
T1a/T1b/T2a P- value* Global P- value*
rs10514231 TT 1.00  
CT 1.18 (0.80–1.76) 0.41 0.46
CC 0.84 (0.46–1.54) 0.57
rs1864182 AA 1.00  
AC 1.22 (0.79–1.89) 0.38 0.52
CC 0.98 (0.57–1.66) 0.93
rs2241880 AA 1.00  
AG 0.88 (0.59–1.33) 0.55 0.02
GG 0.47 (0.27–0.81) 0.01
rs2245214 CC 1.00  
CG 1.46 (0.98–2.17) 0.06 0.14
GG 1.05 (0.57–1.92) 0.88
rs510432 TT 1.00  
CT 1.26 (0.81–1.95) 0.30 0.05
CC 1.84 (1.12–3.02) 0.02
Melanoma Stage 
(≥ Stage T2b vs. Stage T1a/T1b/T2a)
ATG gene SNP Genotype
OR (95% CI) 
(Continuous Stage) P- value* Global P- value*
rs10514231 TT 1 [Reference]   
CT 1.18 (0.90–1.56) 0.23 0.32
CC 0.92 (0.61–1.38) 0.69  
rs1864182 AA 1 [Reference]   
AC 1.07 (0.79–1.46) 0.65 0.90
CC 1.06 (0.74–1.53) 0.74  
rs2241880 AA 1 [Reference]   
AG 1.01 (0.75–1.37) 0.93 0.14
AA 0.74 (0.52–1.06) 0.10  
rs2245214 CC 1 [Reference]   
CG 1.47 (1.11–1.94) 0.01 0.03
GG 1.23 (0.82–1.85) 0.32  
rs510432 TT 1 [Reference]   
CT 1.30 (0.97–1.75) 0.08 0.14
CC 1.37 (0.96–1.95) 0.09  
Genotypic model adjusted for age (continuous), gender, study center, and status. Abbreviations: AJCC, American Joint Committee on Cancer; *P 
values < .05 were considered significant; Bolded results indicate significant associations.
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although not significant at the global P- value. Interestingly, 
rs510432 is located in the 5′ untranslated region (UTR) 
upstream of its first exon in the promotor region. In addi-
tion, this SNP (rs510432) (CC) is associated with asthma 
(P = 0.003)[27] conferring significantly increased promotor 
activity. As we also identified a positive association with 
increased stage and rs510432 (CC) in our population, further 
studies exploring the functional role of this SNP in the 
rate of autophagy and melanoma progression may elucidate 
whether the promoter of ATG5 has increased activity in 
these participants, leading to more advanced stage.
In addition, ATG5 has functions independent of 
autophagy, including critical roles in apoptosis, mitotic 
catastrophe, and regulation of the β- Catenin signaling path-
way [39–41]. As ATG5 is often downregulated in primary 
melanomas [42], the association of two SNPs in this critical 
ATG gene with increased melanoma stage is significant as 
they have the potential to become new markers of mela-
noma risk, progression, and/or therapeutic targets.
No significant associations were identified between the 
five SNPs and ulceration, mitosis, or histological subtype. 
However, while they were not significant at the level of the 
global P- value, rs1864182 (CC) and rs510432 (CC) were 
inversely associated with brisk TILs (OR 0.42; 95% CI = 0.21–
0.88, P = 0.02; OR 0.55; 95% CI = 0.34–0.87, P = 0.01), 
as well as the presence of nonbrisk TILs. The association 
of TILs with autophagy variants is important because higher 
TIL grade in primary melanomas is associated with improved 
melanoma- specific survival [43]. In addition, autophagy’s 
role in modulation of the immune system could have impor-
tant implications for immunotherapy, although the effect 
of this intersection and the role of ATG gene variants on 
TIL grade require further investigation.
Finally, while not significant at the global P- value, an 
inverse association between the homozygous genotype 
(GG) of rs2245214 and scalp/neck melanomas was also 
identified (OR 0.20; 95% CI = 0.05–0.86, P = 0.03). As 
it has been previously documented that individuals with 
scalp/neck melanomas have poorer outcomes than patients 
with melanomas on other sites [44], this inverse relation-
ship warrants further studies to determine if there is a 
functional significance for ATG5 and this anatomic site.
Autophagy has an established role in cancer; however, 
the relationship between genetic variants in autophagy genes 
and melanoma risk and/or progression remains under 
explored. In this study, we assessed the impact of variants 
in critical ATG genes that are necessary for autophagic flux 
in relationship with melanoma prognostic indicators and 
survival. Drugs targeting the autophagy pathway are cur-
rently being investigated as effective therapy for many cancers 
including melanoma. SNPs that alter autophagic rates may 
impact the effectiveness of current treatment strategies and 
thus have clinical significance [7, 30, 45–48]. In silico analysis 
of results from multiple studies, and/or coordination of 
large studies, will be required to assess the reproducibility 
of these ATG gene interactions in melanoma.
This study is limited by the knowledge that alteration 
of autophagy might not be due to variants in ATG genes, 
but possibly due to other signaling pathways that regulate 
autophagy or posttranslational modifications. In addition, 
there are probably other functional genetic variants not 
included in this study, as there are approximately 38 
ATG genes specifically required for autophagy in the yeast 
model Saccharomyces cerevisiae [49]. We did not find a 
direct association between any of the five ATG gene SNPs 
and survival, although this may be due to insufficient 
sample size. Our analyses did not control for multiple 
comparisons, such as false discovery rate. These limita-
tions will have to be addressed in future studies, including 
screening for SNPs in other relevant genes using alterna-
tive technologies, such as deep sequencing, to identify 
variants of interest as well as measuring changes in ATG 
protein levels due to the impact of these SNPs. However, 
our study should be considered exploratory based on the 
fact that it was designed with an a priori hypothesis that 
genetic variants in the autophagy pathway would modify 
risk of melanoma. It should be pointed out that our 
findings confirmed and support other reports addressing 
the impact of these variants in cancer risk as presented 
in the literature and highlight the need for additional 
studies evaluating the functional significance of these SNPs.
In conclusion, we have identified three ATG gene SNPs 
as genetic factors impacting melanoma progression, which, 
in melanoma patients, may result in changes in ATG 
protein levels and alter autophagy regulation, impacting 
melanomagenesis. These findings emphasize the signifi-
cance of the autophagy pathway in melanoma. As the 
role of autophagy in melanoma is complex and context 
dependent, the reported associations may provide impor-
tant insight into how SNPs in critical autophagy genes 
impact melanoma progression.
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